Status:
COMPLETED
Evaluation of the Lungs of Individuals With Lung Disease
Lead Sponsor:
Weill Medical College of Cornell University
Conditions:
Lung Disease
Bronchitis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this protocol is to obtain biologic materials from the blood and lungs from patients with lung disease in order to develop an understanding of the etiology and pathogenesis of these dis...
Detailed Description
Patients will undergo a general medical evaluation by a pulmonary physician (and consultants as appropriate for other organs). The typical routine medical studies to be carried out may include: chest ...
Eligibility Criteria
Inclusion
- Must provide informed consent
- Males and females, age 18 years and older
- Lung disease proven by at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) diseases of organs with known association with lung disease
- Must provide HIV informed consent
Exclusion
- Any history of allergies to xylocaine, lidocaine, versed, valium, atropine, pilocarpine, isoproterenol, terbutaline, aminophylline, or any local anesthetic will not be included in the study
- Drug and/or alcohol abuse within the past six months
- Females who are pregnant or nursing
- Individuals who test positive for HIV (other than for studies directly related to the HIV virus)
Key Trial Info
Start Date :
January 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT00224198
Start Date
January 1 2004
End Date
September 1 2012
Last Update
May 3 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Genetic Medicine, Weill Cornell Medical College
New York, New York, United States, 10021